ALLMedicine™ Secondary Prevention Of Coronary Artery Disease Center
Research & Reviews 47 results
Annals of Internal Medicine; Bates ER
Mar 2nd, 2021 - Xia M, Yang X, Qian C. Meta-analysis evaluating the utility of colchicine in secondary prevention of coronary artery disease. Am J Cardiol. 2021;140:33-8. 33137319.
Future Cardiology; Ortega-Paz L, Capodanno D et. al.
Feb 4th, 2021 - Cardiovascular disease manifestations (CVD) are the world's leading cause of death, and their impact on morbidity requires effective prevention strategies of recurrent adverse events. For decades, inflammation has been proposed as a key promoter f...
Clinical Nutrition ESPEN; Dludla PV, Nkambule BB et. al.
Jan 26th, 2021 - There is a general interest in understanding how the consumption of tea impacts cardiovascular function in individuals at risk of developing cardiovascular disease (CVD). The current review focuses on evidence from randomized controlled trials (RC...
The American Journal of Cardiology; Xia M, Yang X et. al.
Nov 3rd, 2020 - Colchicine has shown potential therapeutic benefits in cardiovascular conditions owing to its broad anti-inflammatory properties. Here, we performed a meta-analysis to determine the efficacy and safety of colchicine in patients with coronary arter...
Cardiology Journal; Jankowski P, Kosior DA et. al.
May 22nd, 2020 - The highest priority in preventive cardiology is given to patients with established coronary artery disease (CAD). The aim of the study was to assess the current implementation of the guidelines for secondary prevention in everyday clinical practi...
Clinicaltrials.gov 8 results
Sep 30th, 2019 - Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the plat...
Sep 12th, 2018 - Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the plat...
Jun 21st, 2018 - The aim of the study is to evaluate the impacts of a cardiac post-discharge management solution in the population of cardiovascular (CVD) patients who were discharged from the hospital. The objectives include two parts: Objective 1: Assess the fea...
May 9th, 2018 - Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor has become the cornerstone for secondary prevention of coronary artery disease. Long-term DAPT is recommended after percutaneous coronary intervention (PCI) in p...
Apr 13th, 2016 - Coronary artery bypass grafting (CABG) surgery is often performed in elderly patients, but non-adherence to post-CABG guideline medications is a common and serious clinical concern in this age group. A recent systematic review found that higher me...
News 6 results
Meghana Halkar, MD, A. Michael Lincoff, MD
Sep 1st, 2016 - Percutaneous coronary intervention for acute coronary syndromes has evolved, and so, hand in hand, has antiplatelet therapy. With the advent of clopidogrel and newer agents, several studies demonstrated the benefits of dual antiplatelet therapy in.
Jun 13th, 2011 - A group of professional societies on June 13 has issued the first set of quality improvement measures that focus on primary and secondary prevention of coronary artery disease and hypertension in the ambulatory setting. The 10 measures were charac.
Abstract and Introduction Clinical guidelines for cholesterol testing and management have been updated recently. With the evolving recognition of benefits and intensified recommendations for cholesterol management, many more patients will require ...
BOSTON — Statin therapy significantly reduces the risk of sudden cardiac death independent of its effect on cholesterol, according to a metaanalysis of 12 studies. “This is not a surprise because statins have a variety of effects, and it is these.
The introduction of the non-vitamin K antagonist oral anticoagulants (NOACs) has been a game changer in our management of many thromboembolic conditions. The relative efficacy, safety, and convenience (rapid onset/offset of action, fewer drug and ...